In a 70 person US safety trial, Kylo 11 lowered lipoprotein(a), a heart risk marker diet can't touch, by up to 97% over 48 weeks. Over half had side effects, none serious.
Read Full Article
#HeartHealth #LipoproteinA #CardioSafetyTrial
Read Full Article
#HeartHealth #LipoproteinA #CardioSafetyTrial
The Lancet
Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a):…
A single dose of Kylo-11 was well tolerated, and at doses of 225 mg or higher, durably
reduced serum lipoprotein(a) concentrations up to 48 weeks.
reduced serum lipoprotein(a) concentrations up to 48 weeks.